The global alpha emitter market size reached US$ 1,150.4 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 5,929.6 Million by 2028, exhibiting a growth rate (CAGR) of 28.37% during 2023-2028.
Alpha emitters are substances emitted by radioactive sources that decay after releasing alpha particles. They achieve appropriate biodistribution and associated dose distribution to achieve effective therapy without causing unacceptable acute or long-term side effects. With their exceptionally high cell-killing rates, alpha particles are more destructive to tumor cells than beta particles when used in medical procedures. Consequently, they cause less damage to adjacent normal tissues. Radium, lead and bismuth are some of the radionuclides used in the treatment process. The short range and high linear energy transfer (LET) of alpha particles have made them remarkably appealing to medical research, particularly as a viable treatment method for cancer. There are numerous types of cancer that can be treated with alpha emitters, including ovarian cancer, pancreatic cancer, lymphoma, and melanoma.
Alpha Emitter Market Trends:
- The market is majorly driven by extensive and high-end research and development (R&D) activities being conducted in cancer treatment. This can be attributed to the growing awareness regarding the cell-killing abilities of targeted alpha emitters. In line with this, the rising prevalence of various types of cancer among the masses is providing an impetus to the market. Also, the increasing geriatric population that is susceptible to develop numerous cardiac and cancer ailments is creating a positive outlook for the market. Moreover, the rising adoption of targeted anticancer or alpha therapy (TAT) in healthcare facilities is impacting the market positively. The market is further propelled by continual technological advancements and the growing number of new nuclear-medicine-based product approvals. Some of the other factors contributing to the market include rapid urbanization, continual improvements in healthcare infrastructure, rising medical expenditure and inflating disposable income levels of the individuals.
Key Market Segmentation:
- IMARC Group provides an analysis of the key trends in each sub-segment of the global alpha emitter market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type of radionuclide, medical application and end user.
Breakup by Type of Radionuclide:
- Astatine
- Radium
- Actinium
- Lead
- Bismuth
- Others
Breakup by Medical Application:
- Prostate Cancer
- Bone Metastasis
- Ovarian Cancer
- Pancreatic Cancer
- Endocrine Tumors
- Others
Breakup by End User:
- Hospitals
- Medical Research Institutions
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
- The competitive landscape of the industry has also been examined along with the profiles of the key players being Actinium Pharmaceuticals Inc., Alpha Tau Medical Ltd., Bayer AG, Fusion Pharmaceuticals, IBA RadioPharma Solutions and RadioMedix Inc.
Key Questions Answered in This Report:
- How has the global alpha emitter market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global alpha emitter market?
- What are the key regional markets?
- What is the breakup of the market based on the type of radionuclide?
- What is the breakup of the market based on the medical application?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global alpha emitter market and who are the key players?
- What is the degree of competition in the industry?